Cytotherapy Journal Citation Rate 2026
1465-3249
eISSN 1477-2566
Elsevier BV
GB
Q3 Quartile
About Cytotherapy
Cytotherapy (C) is a peer-reviewed academic journal covering CAR-T cell therapy research and Hematopoietic Stem Cell Transplantation, published by Elsevier BV in GB, catalogued under ISSN 1465-3249 (e-ISSN 1477-2566). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 1.06 (Q3 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model (APC ~$3300 USD). OpenAlex records 10,026 works and 124,211 citations, with an h-index of 127.
Cytotherapy Citation Rate 2026 — In Context
Cytotherapy has a 2025 2-Year Citation Rate (OpenAlex) of 1.06, placing it in the Q3 quartile within the CAR-T cell therapy research research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Cytotherapy operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view.
Researchers looking to publish in Cytotherapy should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Cytotherapy against similar journals in the field, use our journal comparison tool.
Submission Tips for Cytotherapy
- Budget $3300 for the Article Processing Charge. Check if your institution or funder covers OA fees.
- This journal covers CAR-T cell therapy research, Hematopoietic Stem Cell Transplantation, Mesenchymal stem cell research. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Cytotherapy Compares
Compared against 30 journals in the same research areas.
| ISSN (Print) | 1465-3249 |
|---|---|
| ISSN (Online) | 1477-2566 |
| Publisher | Elsevier BV |
| Country | United Kingdom |
| APC / Cost | $3300 USD |
In-depth profile & metrics
Cytotherapy is published by Elsevier BV and based in United Kingdom. It runs on a subscription or hybrid model with an article-processing charge of USD 3300.
In our subject taxonomy, Cytotherapy is classified under CAR-T cell therapy research, Hematopoietic Stem Cell Transplantation, Mesenchymal stem cell research and Pluripotent Stem Cells Research.
Cytotherapy is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 1.063.
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Cytotherapy
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 1.063 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Compare Journals
Compare Cytotherapy against similar publications in its field:
Related Journals in Your Field
-
Cell Transplantation SAGE IF 64.50
-
Cancer Cell Elsevier IF 64.50
-
Cell Research Springer Nature IF 64.50
-
Cell stem cell Elsevier IF 64.50
-
Cell Biology International Wiley IF 64.50
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S36838616
Get weekly updates for CAR-T cell therapy research journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.